127 related articles for article (PubMed ID: 24444869)
1. Balancing efficacy and safety of JAK inhibitors in myelofibrosis.
Passamonti F
Leuk Res; 2014 Mar; 38(3):290-1. PubMed ID: 24444869
[No Abstract] [Full Text] [Related]
2. Hypothesis: how do JAK2-inhibitors work in myelofibrosis.
Mesa R; Gale RP
Leuk Res; 2009 Sep; 33(9):1156-7. PubMed ID: 19450878
[TBL] [Abstract][Full Text] [Related]
3. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.
Vannucchi AM
Leuk Res; 2009 Dec; 33(12):1581-3. PubMed ID: 19573914
[TBL] [Abstract][Full Text] [Related]
4. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
El Fakih R; Popat U
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
[TBL] [Abstract][Full Text] [Related]
5. JAK2 inhibitors in myelofibrosis.
Pardanani A
Clin Adv Hematol Oncol; 2011 Nov; 9(11):856-8. PubMed ID: 22252617
[No Abstract] [Full Text] [Related]
6. Janus activated kinase inhibition in myelofibrosis.
Malhotra H
Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
[TBL] [Abstract][Full Text] [Related]
7. Emerging targeted therapies in myelofibrosis.
Barosi G
Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
[TBL] [Abstract][Full Text] [Related]
8. [111th Scientific Meeting of the Japanese Society of Internal Medicine: Symposium: 3. Fibrosis of the viscera and its treatment; 5) The pathogenesis and treatment of myelofibrosis].
Shimoda K
Nihon Naika Gakkai Zasshi; 2014 Sep; 103(9):2193-7. PubMed ID: 27522775
[No Abstract] [Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Rondelli D
Haematologica; 2008 Oct; 93(10):1449-50. PubMed ID: 18827262
[No Abstract] [Full Text] [Related]
10. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.
Pardanani A; Abdelrahman RA; Finke C; Lasho TT; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Tefferi A
Leukemia; 2015 Mar; 29(3):741-4. PubMed ID: 25322686
[No Abstract] [Full Text] [Related]
11. Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy.
Harrington PM; Harrison CN
Expert Rev Hematol; 2018 Apr; 11(4):315-324. PubMed ID: 29516749
[TBL] [Abstract][Full Text] [Related]
12. Advances in the understanding and management of primary myelofibrosis.
Cervantes F; Pereira A
Curr Opin Oncol; 2011 Nov; 23(6):665-71. PubMed ID: 21892083
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of pacritinib in myelofibrosis.
Verstovsek S; Komrokji RS
Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
[TBL] [Abstract][Full Text] [Related]
14. [JAK2 inhibitors in the treatment of myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2012 Oct; 53(10):1600-7. PubMed ID: 23037732
[No Abstract] [Full Text] [Related]
15. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
16. How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.
Massaro F; Molica M; Breccia M
Expert Rev Hematol; 2017 Feb; 10(2):155-159. PubMed ID: 27983880
[TBL] [Abstract][Full Text] [Related]
17. [Molecular pathology and treatment for primary myelofibrosis].
Kitanaka A; Shimoda K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():321-5. PubMed ID: 23133975
[No Abstract] [Full Text] [Related]
18. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
Verstovsek S; Talpaz M; Ritchie E; Wadleigh M; Odenike O; Jamieson C; Stein B; Uno T; Mesa RA
Leukemia; 2017 Feb; 31(2):393-402. PubMed ID: 27479177
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.
Pardanani A; Gotlib J; Roberts AW; Wadleigh M; Sirhan S; Kawashima J; Maltzman JA; Shao L; Gupta V; Tefferi A
Leukemia; 2018 Apr; 32(4):1035-1038. PubMed ID: 29263442
[No Abstract] [Full Text] [Related]
20. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
Barba P; Fox ML; Blanco A; Valcárcel D
Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
